The stock of Insmed Incorporated (NASDAQ:INSM) is a huge mover today! The stock increased 4.16% or $0.58 during the last trading session, hitting $14.52. About 271,004 shares traded hands. Insmed Incorporated (NASDAQ:INSM) has risen 15.21% since February 26, 2016 and is uptrending. It has outperformed by 4.78% the S&P500.
The move comes after 9 months positive chart setup for the $854.34 million company. It was reported on Oct, 1 by Barchart.com. We have $23.23 PT which if reached, will make NASDAQ:INSM worth $512.60 million more.
Analysts await Insmed Incorporated (NASDAQ:INSM) to report earnings on November, 4. They expect $-0.57 earnings per share, down 14.00% or $0.07 from last year’s $-0.5 per share. After $-0.59 actual earnings per share reported by Insmed Incorporated for the previous quarter, Wall Street now forecasts -3.39% EPS growth.
Insmed Incorporated (NASDAQ:INSM) Ratings Coverage
Out of 6 analysts covering Insmed (NASDAQ:INSM), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. Insmed has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. UBS downgraded the shares of INSM in a report on Monday, November 9 to “Neutral” rating. Citigroup maintained the shares of INSM in a report on Wednesday, March 16 with “Neutral” rating. The firm earned “Buy” rating on Tuesday, March 15 by Stifel Nicolaus. The stock of Insmed Incorporated (NASDAQ:INSM) has “Buy” rating given on Friday, September 4 by Zacks. The firm has “Hold” rating given on Monday, August 10 by Zacks. Zacks upgraded the shares of INSM in a report on Thursday, August 20 to “Hold” rating. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, October 6.
According to Zacks Investment Research, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.”
Insitutional Activity: The institutional sentiment increased to 1.65 in Q2 2016. Its up 0.69, from 0.96 in 2016Q1. The ratio improved, as 11 funds sold all Insmed Incorporated shares owned while 23 reduced positions. 17 funds bought stakes while 39 increased positions. They now own 55.48 million shares or 0.92% less from 56.00 million shares in 2016Q1.
Pacad Invest holds 0.02% of its portfolio in Insmed Incorporated (NASDAQ:INSM) for 12,537 shares. Tudor Et Al last reported 0.01% of its portfolio in the stock. Emerald Advisers Pa has 630,159 shares for 0.3% of their US portfolio. Janus Management Limited Liability Co owns 2.85 million shares or 0.02% of their US portfolio. Dekabank Deutsche Girozentrale last reported 35,200 shares in the company. The Pennsylvania-based Tfs Ltd Company has invested 0.03% in Insmed Incorporated (NASDAQ:INSM). Jennison Assoc Ltd Llc has 1.20 million shares for 0.01% of their US portfolio. Blackrock Institutional Tru Company Na last reported 0% of its portfolio in the stock. Earnest Partners Limited Liability holds 1,130 shares or 0% of its portfolio. California Public Employees Retirement Sys has invested 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM). The France-based Axa has invested 0.01% in Insmed Incorporated (NASDAQ:INSM). Retail Bank Of America Corp De accumulated 8,775 shares or 0% of the stock. Moreover, Credit Suisse Ag has 0% invested in Insmed Incorporated (NASDAQ:INSM) for 98,698 shares. Deutsche Commercial Bank Ag owns 529,650 shares or 0% of their US portfolio. Alliancebernstein L P reported 86,900 shares or 0% of all its holdings.
More notable recent Insmed Incorporated (NASDAQ:INSM) news were published by: Prnewswire.com which released: “SHAREHOLDER ALERT Rosen Law Firm Reminds Insmed Incorporated Investors of …” on September 07, 2016, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on December 21, 2009, Finance.Yahoo.com published: “INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Insmed …” on September 02, 2016. More interesting news about Insmed Incorporated (NASDAQ:INSM) were released by: Fool.com and their article: “Why Insmed Incorporated Shares Skyrocketed” published on June 18, 2014 as well as Businesswire.com‘s news article titled: “STOCK ALERT: Rosen Law Firm Reminds Insmed Incorporated Investors of Important …” with publication date: July 29, 2016.
INSM Company Profile
Insmed Incorporated, incorporated on March 21, 2013, is a biopharmaceutical company. The Firm operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.